166 CHAPTER 8 S7: RESULTS OF DEFINING THE MOST HOMOGENEOUS AND BEST QUALITY STUDIES FOR META-ANALYSES. Author Year Refer- ence Low risk of bias in the representativeness of the exposed and non-exposed cohort (i.e. both awarded with a star according to the NOS) Uses appropriate guidelines (i.e. SPC, FDA, ESC, EHRA, landmark NOAC trial(s)) Uses a form of propensity adjustment in the analysis of clinical outcomes associated with OLRD and reports a hazard ratio Belongs to the most homogeneous and best quality studies Arbel 2019 114 Yes Yes No No Atarashi 2021 115 Yes Yes No No Briasoulis - D/R 2020 116 Yes No Yes No Briasoulis - D 2020 116 Yes Yes Yes Yes Briasoulis- R 2020 116 Yes No Yes No Cho - R/A 2020 117 Yes Yes No No Cho - R 2020 117 Yes Yes Yes Yes Cho- A 2020 117 Yes Yes Yes Yes de Groot 2020 118 Yes Yes No No Ikeda 2019 119 Yes Yes Yes Yes Inoue 2019 120 Yes No No No Inoue 2020 121 Yes Yes No No Kobayashi 2020 122 Yes No Yes No Lee 2017 123 Yes No Yes No Lee 2019 124 No Yes Yes No Lee 2021 125 Yes Yes Yes Yes Murata 2019 126 Yes No Yes No Ohno 2020 127 Yes No No No Salameh 2020 128 Yes Yes Yes Yes Steinberg 2018 129 Yes Yes Yes Yes Tellor 2017 130 Yes Yes No No Yagi 2019 131 Yes Yes No No Yao - D 2017 132 Yes No Yes No Yao - R 2017 132 Yes Yes Yes Yes Yao - A 2017 132 Yes No Yes No In case articles concern the same author and year, a note is added after the author to indicate what makes the articles distinct. A: apixaban; D: dabigatran; EHRA: European Heart Rhythm Association; ESC: European Society of Cardiology; FDA: Food and Drugs Administration; NOAC: non-vitamin K antagonist oral anticoagulant; NOS: NewcastleOttawa quality assessment Scale for cohort studies; OLRD: off-label reduced dosing; SPC: Summary of Product Characteristic; R: rivaroxaban.
RkJQdWJsaXNoZXIy MTk4NDMw